These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Allergic contact dermatitis caused by Mirvaso®, brimonidine tartrate gel 0.33%, a new topical treatment for rosaceal erythema. Cookson H; McFadden J; White J; White IR Contact Dermatitis; 2015 Dec; 73(6):366-7. PubMed ID: 26768997 [No Abstract] [Full Text] [Related]
3. Topical brimonidine tartrate 0·33% gel effectively reduces the post-treatment erythema of daylight-activated photodynamic therapy. Gerber PA Br J Dermatol; 2016 Jun; 174(6):1422-3. PubMed ID: 26727630 [No Abstract] [Full Text] [Related]
4. Sensitization to and allergic contact dermatitis caused by Mirvaso(®) (brimonidine tartrate) for treatment of rosacea - 2 cases. Bangsgaard N; Fischer LA; Zachariae C Contact Dermatitis; 2016 Jun; 74(6):378-9. PubMed ID: 27133629 [No Abstract] [Full Text] [Related]
5. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study. Layton AM; Schaller M; Homey B; Hofmann MA; Bewley AP; Lehmann P; Nohlgård C; Sarwer DB; Kerrouche N; Ma YM J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2405-10. PubMed ID: 26416154 [TBL] [Abstract][Full Text] [Related]
6. Pulse-Daylight-Photodynamic Therapy in Combination with Corticosteroid and Brimonidine Tartrate for Multiple Actinic Keratoses: A Randomized Clinical Trial. Wiegell SR; Johansen UB; Wulf HC Acta Derm Venereol; 2019 Feb; 99(2):242-243. PubMed ID: 30250962 [No Abstract] [Full Text] [Related]
8. OTC brimonidine (Lumify) for ocular redness. Med Lett Drugs Ther; 2018 Oct; 60(1558):176. PubMed ID: 30335046 [No Abstract] [Full Text] [Related]
9. Topical Brimonidine Tartrate 0.33% Gel on Postlaser Erythema: Our Experience and Review of the Literature. Lee SJ; Kim H; Kim HS Dermatol Surg; 2018 Jan; 44(1):144-147. PubMed ID: 29077635 [No Abstract] [Full Text] [Related]
11. Image Gallery: Brimonidine gel for facial erythema in Netherton syndrome. Filoni A; Vestita M; Giudice G; Bonamonte D Br J Dermatol; 2018 Apr; 178(4):e277. PubMed ID: 29668104 [No Abstract] [Full Text] [Related]
12. Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Fowler J; Jarratt M; Moore A; Meadows K; Pollack A; Steinhoff M; Liu Y; Leoni M; Br J Dermatol; 2012 Mar; 166(3):633-41. PubMed ID: 22050040 [TBL] [Abstract][Full Text] [Related]
14. Contact allergy to cinnamic aldehyde and cinnamic alcohol in Oléophytal. Manzur F; el Sayed F; Bazex J Contact Dermatitis; 1995 Jan; 32(1):55. PubMed ID: 7720382 [No Abstract] [Full Text] [Related]
15. Case Report: Allergic Contact Dermatitis to Topical Brimonidine Demonstrated With Patch Testing: Insights on Evaluation of Brimonidine Sensitization. Ringuet J; Houle MC J Cutan Med Surg; 2018; 22(6):636-638. PubMed ID: 30016883 [No Abstract] [Full Text] [Related]
16. Erythema in Skin Adjacent to Area of Long-term Brimonidine Treatment for Rosacea: A Novel Adverse Reaction. Gillihan R; Nguyen T; Fischer R; Rajpara A; Aires D JAMA Dermatol; 2015 Oct; 151(10):1136-7. PubMed ID: 26083825 [No Abstract] [Full Text] [Related]
17. Brimonidine tartrate 0.33% gel for the management of posttreatment erythema induced by laser skin resurfacing. Braun SA; Artzi O; Gerber PA J Am Acad Dermatol; 2017 Feb; 76(2):e53-e55. PubMed ID: 28089013 [No Abstract] [Full Text] [Related]
18. A case of bilateral deep stromal corneal opacity and vascularization after use of multiple antiglaucoma medications including brimonidine tartrate ophthalmic solution. Tsujinaka A; Takai Y; Inoue Y; Tanito M Acta Ophthalmol; 2019 Sep; 97(6):e948-e949. PubMed ID: 30609169 [No Abstract] [Full Text] [Related]